Article Figures & Data
Figures
- Figure 1.
The boxplots of the GSTP1-1 (ng/mL) concentrations in oCF by histologic subtype of patients with malignant (n = 56), borderline (n = 21), and benign (n = 88) ovarian tumors.
- Figure 2.
Kaplan-Meier estimates of DFS (A) and of OS (B) of patients who received chemotherapy (n = 30). The group with low GSTP1-1 values (≤160 ng/mL; solid line) and the group with high GSTP1-1 values (>160 ng/mL; broken line) include 12 and 18 patients, respectively. Vertical bars, patients with censored data.
Tables
- Table 1.
Median (range) GSTP1-1 cyst fluid concentrations (ng/mL) by clinicopathologic parameters and of patients with EOC (n = 56)
n (%) Cyst fluid median GSTP1-1 (range) P FIGO stage 0.010* I + II 27 (48) 162 (10-1,302) III + IV 28 (50) 703 (10-32,695) Unknown 1 (2) Tumor grade 0.044* Low-grade 14 (25) 89 (10-1,302) High-grade 37 (66) 448 (10-32,695) Unknown 5 (9) Histology 0.264† Serous 24 (43) 224 (10-25,963) Mucinous 15 (27) 114 (10-32,695) Endometrioid 12 (21) 447 (28-3,583) Other‡ 5 (9) 881 (362-2,384) Residual tumor 0.301* <1 cm 38 (68) 299 (10-3,583) ≥1 cm 18 (32) 617 (10-32,695) Malignant cells in ascites 0.101* No 25 (45) 162 (12-13,020) Yes 28 (50) 535 (10-32,695) Unknown 3 (5) Preoperative CA 125 0.010* ≤126 U/mL 27 (48) 114 (10-960) >126 U/mL 26 (47) 594 (10-32,695) Unknown 3 (5) Total 56 (100) 383 (10-32,695) - Table 2.
HR with 95% CI of DFS and of OS by clinicopathologic parameters of patients with EOC who received six courses of adjuvant platinum-based chemotherapy (n = 30), using univariate Cox Regression
n DFS (95% CI) P OS (95% CI) P HR HR GSTP1-1 Low (≤160 ng/mL) 12 1.00 (Reference) 1.00 (Reference) High (>160 ng/mL) 18 2.79 (0.97-8.04) 0.058* 4.50 (0.97-20.92) 0.055* FIGO stage I + II 11 1.00 (Reference) 1.00 (Reference) III + IV 19 10.17 (2.25-45.99) 0.003* 3.12 (0.84-11.59) 0.089* Residual disease <1 cm 18 1.00 (Reference) 1.00 (Reference) ≥1 cm 12 1.56 (0.52-4.67) 0.424 1.06 (0.28-4.03) 0.935 Malignant cells in ascites No 9 1.00 (Reference) 1.00 (Reference) Yes 20 5.07 (1.14-22.65) 0.033* 2.30 (0.61-8.67) 0.218 Preoperative CA 125 ≤126 U/mL 11 1.00 (Reference) 1.00 (Reference) >126 U/mL 18 2.65 (0.82-8.60) 0.104 4.97 (1.06-23.20) 0.041* ↵*Parameters with a P value of ≤0.10 were selected for multivariate analysis.
- Table 3.
Published reports on outcomes of the relationship between GSTP1-1 levels and response to chemotherapy and survival including the methods used for tissue analysis of GSTP1-1
Reference n Method used for analysis of GSTP1-1 Correlation between GSTP1-1 and response to chemotherapy Correlation between GSTP1-1 and survival Van der Zee et al. 17 High performance liquid chromatography No — Green et al. 78 Immunohistochemistry Yes Yes Hamada et al. 61 Immunohistochemistry Yes Yes Van der Zee et al. 89 Immunohistochemistry No No Hirazono et al. 36 Immunohistochemistry — Yes Wrigley et al. 66 Immunohistochemistry No No Western blotting No No Ghazal-Aswad et al. 39 Immunohistochemistry No — Cheng et al. 20 Immunohistochemistry Yes — Western blotting — No Kase et al. 87 Immunohistochemistry Yes — Satoh et al. 67 Immunohistochemistry — Yes Ikeda et al. 93 Immunohistochemistry — No Howells et al. 77 Immunohistochemistry No No Saip et al. 55 Immunohistochemistry No No
Volume 18, Issue 8
